Dr. Jennifer A. Belsky
Claim this profileRiley Hospital for Children
Studies Lymphoma
Studies Hodgkin's Lymphoma
3 reported clinical trials
11 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
Stage I
2Hodgkin's Lymphoma
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Jennifer A. Belsky is currently running
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
Nivolumab + Chemo-Immunotherapy
for Large B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Recruiting2 awards Phase 321 criteria
More about Jennifer A. Belsky
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jennifer A. Belsky has experience with
- Nivolumab
- Brentuximab Vedotin
- Doxorubicin Hydrochloride
- Radiation Therapy
- Cyclophosphamide
- Dacarbazine
Breakdown of trials Jennifer A. Belsky has run
Lymphoma
Hodgkin's Lymphoma
Multiple Sclerosis
B-Cell Lymphoma
Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer A. Belsky specialize in?
Jennifer A. Belsky focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Jennifer A. Belsky currently recruiting for clinical trials?
Yes, Jennifer A. Belsky is currently recruiting for 2 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Jennifer A. Belsky has studied deeply?
Yes, Jennifer A. Belsky has studied treatments such as Nivolumab, Brentuximab Vedotin, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Jennifer A. Belsky?
Apply for one of the trials that Jennifer A. Belsky is conducting.
What is the office address of Jennifer A. Belsky?
The office of Jennifer A. Belsky is located at: Riley Hospital for Children, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Riley Hospital for Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.